Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03248531 · ClinicalTrials.gov registry record · Phase 2
A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa.
A Phase 2 study, sponsored by UCB Biopharma SRL.
- Completed
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
NCT03248531 is a Phase 2 study that has completed, run by UCB Biopharma SRL. The registered enrollment target is 90 participants.
The verdict
NCT03248531, a Phase 2 study, has completed, sponsored by UCB Biopharma SRL.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
Study Summary
Hidradenitis suppurativa (HS) is a painful, long-term skin condition that causes abscesses and scarring on the skin.
Interventions
- OTHER Placebo
- DRUG Adalimumab
- DRUG Bimekizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2017-09-22 |
| Est. Completion | 2019-02-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03248531
The ClinicalTrials.gov registry entry for NCT03248531 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Biopharma SRL, which has 82 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03248531 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03248531 about?
NCT03248531 is a clinical study titled "A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa.". Hidradenitis suppurativa (HS) is a painful, long-term skin condition that causes abscesses and scarring on the skin.
What is the current status of trial NCT03248531?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2017-09-22. Estimated completion is 2019-02-21.
What interventions are being tested in trial NCT03248531?
The interventions under investigation include: Placebo (OTHER), Adalimumab (DRUG), Bimekizumab (DRUG).
Who is sponsoring clinical trial NCT03248531?
This trial is sponsored by UCB Biopharma SRL, which has 82 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.